カテゴリ： GlobalData, アメリカ, 企業調査

U.S. Department of Health and Human Services-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：U.S. Department of Health and Human Services - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013366
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：263
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
U.S. Department of Health and Human Services (HHS) is a healthcare service provider that offers patient care and support services. The organization’s service areas include health insurance marketplace, mental health, food safety, fighting HIV or AIDS, supporting military families, statistics, medicare fraud, and flu prevention. It also provides social services, prevention and wellness; providers and facilities; public health and safety; and emergency preparedness and response programs. The organization operates in Boston, District of Columbia, Atlanta, Chicago, Kansas City, Dallas, Denver, San Francisco, and Seattle. HHS is headquartered in Washington D.C., the US.

U.S. Department of Health and Human Services – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 8
List of Figures 11
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 13
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 14
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 15
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 16
U.S. Department of Health and Human Services, Medical Devices Deals, 2011 to YTD 2017 17
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 18
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deal Details 34
Venture Financing 34
Aura Biosciences Secures An Additional US$3 Million In Series A Financing 34
Partnerships 35
BiondVax Pharma Enters into Agreement with National Institute of Allergy and Infectious Diseases 35
Inspyr Therapeutics Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 36
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority for Infectious Diseases 37
Emergent BioSolutions Enters into Agreement with BARDA 38
Janssen Research & Development Enters into Agreement with U.S. Department of Health 39
Geom Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 40
Zavante Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Disease 41
Summit (Oxford) Enters into Contract with Biomedical Advanced Research and Development Authority 42
Retrophin Enters into Research Agreement with National Center for Advancing Translational Sciences and NGLY1 43
SillaJen Enters into R&D Agreement with National Cancer Institute 44
Xcovery Partners with National Cancer Institute and Children’s Oncology Group 45
Cancer Prevention Pharma Enters into Partnership with National Cancer Institute and Vanderbilt University Medical Center 46
Race Oncology Enters into Agreement with National Cancer Institute 47
Maxcyte Enters into R&D Agreement with National Institute of Allergy and Infectious Diseases 48
Eleven Biotherapeutics Enters into R&D Agreement with National Cancer Institute and Astrazeneca 49
Lixte Biotech Enters into R&D Agreement with the National Cancer Institute 50
Abeome Enters into Research Agreement with Centers for Disease Control and Prevention 51
Pandomedx Enters Into Collaboration with National Cancer Institute 52
DesignMedix Enters into Agreement with The National Institute of Allergy and Infectious Diseases 53
ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 54
Oncoceutics Enters into Research Agreement with National Institutes of Health 55
Cyprium Therapeutics Enters into Research and Development Agreement with Eunice Kennedy Shriver NICHD 56
Achieve Life Science and OncoGenex Pharma Enter into Partnership with National Institutes of Health 57
Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 58
Chrysalis BioTherapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 59
Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 60
Agenus Enters into Agreement with National Cancer Institute 61
Threshold Pharma Enters into Agreement with National Cancer Institute 62
Syndax Pharma Enters into Co-Development Agreement with National Cancer Institute 63
Immunovia to Enter into Agreement with National Cancer Institute 64
Pfizer Enters into Agreement with National Cancer Institute 65
Epizyme Enters into Research Agreement with National Cancer Institute 66
Human Metabolome Technologies Enters into Agreement with National Institute on Aging 67
Atrin Pharma Enters into Agreement with National Cancer Institute 68
Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention 69
NewLink Genetics Enters into Agreement with BARDA 70
Riptide Bioscience Enters into Agreement with National Cancer Institute 71
Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 72
PapGene Enters into Agreement with National Cancer Institute 73
Sanofi Pasteur Enters into Contract with US Department of Health and Human Services 74
Cellerant Therapeutics Enters into Contract with National Institutes of Health 75
The Medicines Company Enters into Agreement with BARDA 76
Protein Sciences Enters into Agreement with Biomedical Advanced Research and Development Authority 77
Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 78
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 79
University of Pittsburgh Cancer Institute Enters into Contract with National Cancer Institute 80
Cellectar Biosciences Enters into Contract with National Cancer Institute 81
Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 82
Altimmune Enters into Contract Agreement with BARDA for NasoShield 83
Evolva Enters into Agreement with National Institute of Allergy and Infectious Diseases 84
RedHill Biopharma Enters into Agreement with NIAID 85
Emergent BioSolutions Partners with Biomedical Advanced Research and Development Authority 86
Agilis Biotherapeutics Partners with National Center for Accelerating Translational Sciences 87
Cellular Dynamics International Enters into R&D Agreement with National Eye Institute 88
Kite Pharma Enters into R&D Agreement with National Cancer Institute 89
Cerus Enters into Partnership with Biomedical Advanced Research and Development Authority 90
Flatiron Health Enters into Research Agreement with US Food and Drug Administration 91
Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 92
Basilea Pharmaceutica International Enters into Agreement with Biomedical Advanced Research and Development Authority 93
Altor BioScience Enters into Co-Development Agreement with National Cancer Institute 94
NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 95
GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 96
Eagle Pharma Enters into Agreement with National Institutes of Health 97
Asterand Bioscience Enters into Contract Agreement with National Institutes of Health 98
PDS Biotechnology Enters into R&D Agreement with National Cancer Institute 99
New England Research Institutes Enters into Research Agreement with National Heart Lung and Blood Institute 100
Regen BioPharma Enters into Research Agreement with National Institutes of Health 101
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 102
OriGene Technologies Enters into Contract with National Cancer Institute 103
SolaranRx Enters into R&D Agreement with National Cancer Institute 104
Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 105
Precision Biologics Enters into R&D Agreement with National Cancer Institute 106
Cancer Targeted Technology Enters into Contract Agreement with National Cancer Institute 107
GlaxoSmithKline Enters into Research Agreement with NIAID 108
Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 109
PepTcell Enters into Research and Development Agreement National Institute of Allergy and Infectious Diseases 110
Vaxart Enters into Contract with BARDA 111
SNBL USA Enters into Contract with BARDA 112
Saint Louis University Enters into Agreement with National Institutes of Health 113
SRI International Enters into Biological Testing Facility Contract with NICHD 114
KIYATEC Enters into Research Contract with National Cancer Institute 115
Vince & Associates Partners with US FDA Office of Generic Drugs 116
Protein Foundry Enters into Research Contract with NHLBI 117
SuviCa Enters into Contract with National Cancer Institute 118
SRI International Enters into Agreement with National Institute of Allergy and Infectious Diseases 119
Centers for Disease Control and Prevention Enters into R&D Agreement with Nanomedical Diagnostics 120
Pharma Product Development Enters into Agreement with BARDA 121
Galena Biopharma Enters into Agreement with National Cancer Institute 122
Regeneron Pharma Enters into Development Agreement with BARDA 123
Dimension Therapeutics Enters into R&D Agreement with Eunice Kennedy Shriver National Institute 124
WiCell Research Institute Enters into Distribution Agreement with NHLBI 125
Etubics Enters into R&D Agreement with National Cancer Institute 126
CDC Foundation Enters into Agreement with Pfizer and Centers for Disease Control and Prevention 127
GenSight Biologics Enters into Research Agreement with Pierre and Marie Curie University, INSERM and CNRS 128
Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 129
FirstString Research Enters into R&D Agreement with NCATS 130
Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 131
GenVec Enters into Research Agreement with LMIV 132
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 133
BioAegis Therapeutics Enters into Research Agreement with the National Institute of Allergy and Infectious Disease 134
Intrexon Enters into R&D Agreement with National Cancer Institute 135
Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 136
Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 138
VistaGen Therapeutics Enters into R&D Agreement with National Institute of Mental Health 139
MedImmune Enters into Co-Development Agreement with National Cancer Institute 140
Addex Therapeutics Enters into Partnership with National Institute on Alcohol Abuse and Alcoholism 141
Vtesse Enters into Agreement with National Institutes of Health for VTS-270 142
uBiome Enters into Research Agreement with Centers for Disease Control and Prevention 143
ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 144
Accelerate Diagnostics Enters into Co-Development Agreement with Centers for Disease Control and Prevention 145
GenSight Biologics Enters into Research Agreement with UPMC, INSERM and CNRS 146
Atox Bio Enters into Contract Agreement with BARDA for AB103 147
PharmAthene Enters into Agreement with National Institutes of Allergy and Infectious Diseases 148
Kadmon Enters into R&D Agreement with NIDCR 149
Foamix Enters into Co-Development Agreement with National Eye Institute 150
New Amsterdam Sciences to Enter into Research Agreement with National Institute of Health 151
Paradigm Shift Therapeutics Enters into Agreement with National Cancer Institute 152
Organovo Enters Into Co-Development Agreement With National Center For Advancing Translational Sciences And National Institutes of Health 153
Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 154
Lixte Biotech Enters into R&D Agreement with National Institute of Neurological Disorders and Stroke 155
Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 156
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 157
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 158
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 159
National Cancer Institute Enters Into Co-Development Agreement With Seoul National University Hospital For Proteomic Technologies 160
Kite Pharma Enters Into R&D Agreement With National Cancer Institute For Cellular Immunotherapy Products 161
Cytori Therapeutics Amends its Agreement with Biomedical Advanced Research and Development Authority 163
Diurnal Extends Cooperative Research and Development Agreement with National Institutes of Health 164
DFH Pharma Enters Into Co-Development Agreement With NIAID For HIV Maturation Inhibitor Drugs 165
Rockland Immunochemicals Enters Into Co-Development Agreement With National Cancer Institute 166
ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 167
Delcath Systems Extends Co-Development Agreement With National Cancer Institute 168
FEI Enters Into R&D Agreement With NIH 169
DFH Pharma Enters Into Co-Development Agreement With National Cancer Institute 170
Raptor Pharma Enters Into Co-Development Agreement With NIDDK For RP104 171
Concert Pharma Enters Into Research Agreement With NIH 173
AVI BioPharma Enters Into Co-Development Agreement With National Institutes of Health For Exon 50 174
BN ImmunoTherapeutics Expands Co-Development Agreement With National Cancer Institute 175
Afraxis Enters Into Co-Development Agreement With National Institutes of Health 176
Aura Biosciences Enters Into Research And Development Agreement With NIH 177
Lion Biotech Amends Co-Development Agreement with National Cancer Institute 178
Genesis Biopharma Enters Into Co-Development Agreement With The National Cancer Institute 179
Pharmacyclics Enters Into Co-Development Agreement With National Cancer Institute For PCI-32765 180
Viamet Pharma Enters Into Co-Development Agreement With National Institutes of Health 182
GNS Healthcare Enters Into An Agreement With National Cancer Institute 183
Amsterdam Molecular Enters Into Cooperative Research and Development Agreement With National Institutes of Health 184
New Zealand Pharma Enters Into Co-Development Agreement With National Human Genome Research Institute For DEX-M74 185
RRD International Enters Into Co-Development Agreement With National Institutes of Health Therapeutics For Rare And Neglected Diseases 186
Licensing Agreements 187
Salubris Biotherapeutics to Enter into Licensing Agreement with National Institutes of Health 187
Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 188
NICHD Enters into Licensing Agreement with Cyprium Therapeutics 190
PaxVax Enters into Licensing Agreement with National Institutes of Health 191
ConverGene Enters into Licensing Agreement with National Center for Advancing Translational Sciences 192
Medigen Vaccine Biologics Expands Licensing Agreement with National Institutes of Health for Dengue Vaccine 193
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 194
Cogentis Therapeutics to Enter into Licensing Agreement with National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services 195
Oblique Therapeutics Enters Licensing Agreement with National Institutes of Health and Karolinska Institutet 196
Great Lakes Neuroscience Enters into Licensing Agreement with National Institutes of Health 197
Elixirgen Enters into License Agreement with National Institute on Aging 198
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 199
Lion Biotech Enters into Licensing Agreement with National Institutes of Health 201
Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 202
JSK Therapeutics Enters Into Licensing Agreement with NIH Office of Technology Transfer 203
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 204
Genesis Biopharma Enters Into Patent Licensing Agreement With National Institutes Of Health 205
Lion Biotech Amends Licensing Agreement with National Institutes of Health 206
Biologics Resources Enters into Licensing Agreement with National Institutes of Health 207
uniQure Amends Licensing Agreement with National Institutes of Health for AAV5 Products 208
Microbiotix Receives Notice for Exclusive Patent License from National Institutes of Health 209
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 210
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 211
Butantan Institute Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 212
Vtesse Enters into Licensing Agreement with National Institutes of Health for Cyclodextrins 213
Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 214
Exxell BIO Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 216
Peptron Enters into Licensing agreement with National Institutes of Health 217
KannaLife Sciences Enters Into Licensing Agreement With NIH 218
Organic Vaccines Enters into Licensing Agreement with National Institutes of Health 219
Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 220
Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 221
Bavarian Nordic Enters into Licensing Agreement with National Institutes of Health 222
Radiation Control Technologies Enters Into Licensing Agreement With National Institutes of Health 223
NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 224
KannaLife Sciences Enters Into Licensing Agreement With NIH-OTT 225
BioDigitalValley Enters Into Licensing Agreement With National Library of Medicine 226
BN ImmunoTherapeutics Enters Into Licensing Agreement With National Institutes of Health 227
Amsterdam Molecular Expands Licensing Agreement With National Institutes Of Health 228
Ariadne Genomics Extends Licensing Agreement With NCI For Pathway Studio 229
U.S. Department of Health and Human Services – Key Employees 230
U.S. Department of Health and Human Services – Locations And Subsidiaries 231
Head Office 231
Other Locations & Subsidiaries 231
Joint Venture 233
Recent Developments 234
Government and Public Interest 234
Aug 16, 2017: Scientists give star treatment to lesser-known cells crucial for brain development 234
Aug 15, 2017: HHS awards nearly $105 million to improve health center quality 236
Jul 19, 2017: Oahu Community Health Centers Receive $3 Million to Expand Health Services 237
May 31, 2017: HHS announces over $70 million in grants to address the opioid crisis 238
Dec 15, 2016: Department of Health and Human Services awards over $50 Million for new health center sites 239
Dec 01, 2016: Castro Announces $5.29M for UTSA Brain Health Research 240
Sep 15, 2016: HHS awards over $87 million for health centers’ IT enhancements 241
Sep 14, 2016: New data show major improvements in health care access, affordability, and quality under the Affordable Care Act 242
Sep 07, 2016: Molina Healthcare Announces Support for HHS’ Efforts to Improve the Marketplace Benefit and Payment Parameters 244
Aug 25, 2016: United States Surgeon General appeals to America’s clinicians to “Turn the Tide” on the prescription drug epidemic 245
Aug 18, 2016: HHS awards more than $100 million to improve health center quality 246
Aug 11, 2016: $10 Million in Grants Targets Community-Based Efforts to Combat Chronic Diseases in the Delta Region 247
Aug 04, 2016: HHS awards more than $8.6 million for Health Centers to Improve Care Coordination and Become Patient-Centered Medical Homes 248
Jul 26, 2016: Secretary Burwell Highlights Bundled Payments, Future of Delivery System Reform in Florida 249
Jul 25, 2016: Important Next Step towards a Better, Smarter, Healthier Medicare: New Payment Models and Rewards for Better Care at Lower Cost 250
Jul 20, 2016: HRSA Awards More Than $149 million to Grow the Nation’s Primary Care Workforce and Expand Health Professions Training 252
Jul 06, 2016: HHS announces new actions to combat opioid epidemic 253
Apr 18, 2016: Diabetes drug, metformin, lowers risk of heart disease deaths better than sulfonylureas 255
Mar 11, 2016: HHS awards $94 million to health centers to help treat the prescription opioid abuse and heroin epidemic in America 257
Product News 258
Sep 18, 2017: HHS partners to develop first intranasal treatment for cyanide poisoning 258
Feb 25, 2016: Medidata’s Cloud Technology Powers U.S. Government Research on Drug Development Costs 259
Jan 19, 2017: Northwestern University: Clinical Trials Evaluate New Treatment for Anal Cancer 260
Other Significant Developments 261
Oct 05, 2017: HHS Awards ICF $25 Million Public Health Preparedness IDIQ 261
Dec 05, 2016: CVS Health and HHS Study Finds Proactive Pharmacy-based Outreach Helps Patients Access Needed Medications during a Natural Disaster 262
Appendix 263
Methodology 263
About GlobalData 263
Contact Us 263
Disclaimer 263

List of Tables
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Key Facts 2
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 13
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 14
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 15
U.S. Department of Health and Human Services, Deals By Therapy Area, 2011 to YTD 2017 16
U.S. Department of Health and Human Services, Medical Devices Deals, 2011 to YTD 2017 17
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 18
Aura Biosciences Secures An Additional US$3 Million In Series A Financing 34
BiondVax Pharma Enters into Agreement with National Institute of Allergy and Infectious Diseases 35
Inspyr Therapeutics Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 36
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority for Infectious Diseases 37
Emergent BioSolutions Enters into Agreement with BARDA 38
Janssen Research & Development Enters into Agreement with U.S. Department of Health 39
Geom Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 40
Zavante Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Disease 41
Summit (Oxford) Enters into Contract with Biomedical Advanced Research and Development Authority 42
Retrophin Enters into Research Agreement with National Center for Advancing Translational Sciences and NGLY1 43
SillaJen Enters into R&D Agreement with National Cancer Institute 44
Xcovery Partners with National Cancer Institute and Children’s Oncology Group 45
Cancer Prevention Pharma Enters into Partnership with National Cancer Institute and Vanderbilt University Medical Center 46
Race Oncology Enters into Agreement with National Cancer Institute 47
Maxcyte Enters into R&D Agreement with National Institute of Allergy and Infectious Diseases 48
Eleven Biotherapeutics Enters into R&D Agreement with National Cancer Institute and Astrazeneca 49
Lixte Biotech Enters into R&D Agreement with the National Cancer Institute 50
Abeome Enters into Research Agreement with Centers for Disease Control and Prevention 51
Pandomedx Enters Into Collaboration with National Cancer Institute 52
DesignMedix Enters into Agreement with The National Institute of Allergy and Infectious Diseases 53
ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 54
Oncoceutics Enters into Research Agreement with National Institutes of Health 55
Cyprium Therapeutics Enters into Research and Development Agreement with Eunice Kennedy Shriver NICHD 56
Achieve Life Science and OncoGenex Pharma Enter into Partnership with National Institutes of Health 57
Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 58
Chrysalis BioTherapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 59
Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 60
Agenus Enters into Agreement with National Cancer Institute 61
Threshold Pharma Enters into Agreement with National Cancer Institute 62
Syndax Pharma Enters into Co-Development Agreement with National Cancer Institute 63
Immunovia to Enter into Agreement with National Cancer Institute 64
Pfizer Enters into Agreement with National Cancer Institute 65
Epizyme Enters into Research Agreement with National Cancer Institute 66
Human Metabolome Technologies Enters into Agreement with National Institute on Aging 67
Atrin Pharma Enters into Agreement with National Cancer Institute 68
Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention 69
NewLink Genetics Enters into Agreement with BARDA 70
Riptide Bioscience Enters into Agreement with National Cancer Institute 71
Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 72
PapGene Enters into Agreement with National Cancer Institute 73
Sanofi Pasteur Enters into Contract with US Department of Health and Human Services 74
Cellerant Therapeutics Enters into Contract with National Institutes of Health 75
The Medicines Company Enters into Agreement with BARDA 76
Protein Sciences Enters into Agreement with Biomedical Advanced Research and Development Authority 77
Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 78
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 79
University of Pittsburgh Cancer Institute Enters into Contract with National Cancer Institute 80
Cellectar Biosciences Enters into Contract with National Cancer Institute 81
Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 82
Altimmune Enters into Contract Agreement with BARDA for NasoShield 83
Evolva Enters into Agreement with National Institute of Allergy and Infectious Diseases 84
RedHill Biopharma Enters into Agreement with NIAID 85
Emergent BioSolutions Partners with Biomedical Advanced Research and Development Authority 86
Agilis Biotherapeutics Partners with National Center for Accelerating Translational Sciences 87
Cellular Dynamics International Enters into R&D Agreement with National Eye Institute 88
Kite Pharma Enters into R&D Agreement with National Cancer Institute 89
Cerus Enters into Partnership with Biomedical Advanced Research and Development Authority 90
Flatiron Health Enters into Research Agreement with US Food and Drug Administration 91
Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 92
Basilea Pharmaceutica International Enters into Agreement with Biomedical Advanced Research and Development Authority 93
Altor BioScience Enters into Co-Development Agreement with National Cancer Institute 94
NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 95
GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 96
Eagle Pharma Enters into Agreement with National Institutes of Health 97
Asterand Bioscience Enters into Contract Agreement with National Institutes of Health 98
PDS Biotechnology Enters into R&D Agreement with National Cancer Institute 99
New England Research Institutes Enters into Research Agreement with National Heart Lung and Blood Institute 100
Regen BioPharma Enters into Research Agreement with National Institutes of Health 101
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 102
OriGene Technologies Enters into Contract with National Cancer Institute 103
SolaranRx Enters into R&D Agreement with National Cancer Institute 104
Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 105
Precision Biologics Enters into R&D Agreement with National Cancer Institute 106
Cancer Targeted Technology Enters into Contract Agreement with National Cancer Institute 107
GlaxoSmithKline Enters into Research Agreement with NIAID 108
Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 109
PepTcell Enters into Research and Development Agreement National Institute of Allergy and Infectious Diseases 110
Vaxart Enters into Contract with BARDA 111
SNBL USA Enters into Contract with BARDA 112
Saint Louis University Enters into Agreement with National Institutes of Health 113
SRI International Enters into Biological Testing Facility Contract with NICHD 114
KIYATEC Enters into Research Contract with National Cancer Institute 115
Vince & Associates Partners with US FDA Office of Generic Drugs 116
Protein Foundry Enters into Research Contract with NHLBI 117
SuviCa Enters into Contract with National Cancer Institute 118
SRI International Enters into Agreement with National Institute of Allergy and Infectious Diseases 119
Centers for Disease Control and Prevention Enters into R&D Agreement with Nanomedical Diagnostics 120
Pharma Product Development Enters into Agreement with BARDA 121
Galena Biopharma Enters into Agreement with National Cancer Institute 122
Regeneron Pharma Enters into Development Agreement with BARDA 123
Dimension Therapeutics Enters into R&D Agreement with Eunice Kennedy Shriver National Institute 124
WiCell Research Institute Enters into Distribution Agreement with NHLBI 125
Etubics Enters into R&D Agreement with National Cancer Institute 126
CDC Foundation Enters into Agreement with Pfizer and Centers for Disease Control and Prevention 127
GenSight Biologics Enters into Research Agreement with Pierre and Marie Curie University, INSERM and CNRS 128
Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 129
FirstString Research Enters into R&D Agreement with NCATS 130
Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 131
GenVec Enters into Research Agreement with LMIV 132
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 133
BioAegis Therapeutics Enters into Research Agreement with the National Institute of Allergy and Infectious Disease 134
Intrexon Enters into R&D Agreement with National Cancer Institute 135
Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 136
Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 138
VistaGen Therapeutics Enters into R&D Agreement with National Institute of Mental Health 139
MedImmune Enters into Co-Development Agreement with National Cancer Institute 140
Addex Therapeutics Enters into Partnership with National Institute on Alcohol Abuse and Alcoholism 141
Vtesse Enters into Agreement with National Institutes of Health for VTS-270 142
uBiome Enters into Research Agreement with Centers for Disease Control and Prevention 143
ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 144
Accelerate Diagnostics Enters into Co-Development Agreement with Centers for Disease Control and Prevention 145
GenSight Biologics Enters into Research Agreement with UPMC, INSERM and CNRS 146
Atox Bio Enters into Contract Agreement with BARDA for AB103 147
PharmAthene Enters into Agreement with National Institutes of Allergy and Infectious Diseases 148
Kadmon Enters into R&D Agreement with NIDCR 149
Foamix Enters into Co-Development Agreement with National Eye Institute 150
New Amsterdam Sciences to Enter into Research Agreement with National Institute of Health 151
Paradigm Shift Therapeutics Enters into Agreement with National Cancer Institute 152
Organovo Enters Into Co-Development Agreement With National Center For Advancing Translational Sciences And National Institutes of Health 153
Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 154
Lixte Biotech Enters into R&D Agreement with National Institute of Neurological Disorders and Stroke 155
Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 156
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 157
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 158
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 159
National Cancer Institute Enters Into Co-Development Agreement With Seoul National University Hospital For Proteomic Technologies 160
Kite Pharma Enters Into R&D Agreement With National Cancer Institute For Cellular Immunotherapy Products 161
Cytori Therapeutics Amends its Agreement with Biomedical Advanced Research and Development Authority 163
Diurnal Extends Cooperative Research and Development Agreement with National Institutes of Health 164
DFH Pharma Enters Into Co-Development Agreement With NIAID For HIV Maturation Inhibitor Drugs 165
Rockland Immunochemicals Enters Into Co-Development Agreement With National Cancer Institute 166
ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 167
Delcath Systems Extends Co-Development Agreement With National Cancer Institute 168
FEI Enters Into R&D Agreement With NIH 169
DFH Pharma Enters Into Co-Development Agreement With National Cancer Institute 170
Raptor Pharma Enters Into Co-Development Agreement With NIDDK For RP104 171
Concert Pharma Enters Into Research Agreement With NIH 173
AVI BioPharma Enters Into Co-Development Agreement With National Institutes of Health For Exon 50 174
BN ImmunoTherapeutics Expands Co-Development Agreement With National Cancer Institute 175
Afraxis Enters Into Co-Development Agreement With National Institutes of Health 176
Aura Biosciences Enters Into Research And Development Agreement With NIH 177
Lion Biotech Amends Co-Development Agreement with National Cancer Institute 178
Genesis Biopharma Enters Into Co-Development Agreement With The National Cancer Institute 179
Pharmacyclics Enters Into Co-Development Agreement With National Cancer Institute For PCI-32765 180
Viamet Pharma Enters Into Co-Development Agreement With National Institutes of Health 182
GNS Healthcare Enters Into An Agreement With National Cancer Institute 183
Amsterdam Molecular Enters Into Cooperative Research and Development Agreement With National Institutes of Health 184
New Zealand Pharma Enters Into Co-Development Agreement With National Human Genome Research Institute For DEX-M74 185
RRD International Enters Into Co-Development Agreement With National Institutes of Health Therapeutics For Rare And Neglected Diseases 186
Salubris Biotherapeutics to Enter into Licensing Agreement with National Institutes of Health 187
Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 188
NICHD Enters into Licensing Agreement with Cyprium Therapeutics 190
PaxVax Enters into Licensing Agreement with National Institutes of Health 191
ConverGene Enters into Licensing Agreement with National Center for Advancing Translational Sciences 192
Medigen Vaccine Biologics Expands Licensing Agreement with National Institutes of Health for Dengue Vaccine 193
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 194
Cogentis Therapeutics to Enter into Licensing Agreement with National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services 195
Oblique Therapeutics Enters Licensing Agreement with National Institutes of Health and Karolinska Institutet 196
Great Lakes Neuroscience Enters into Licensing Agreement with National Institutes of Health 197
Elixirgen Enters into License Agreement with National Institute on Aging 198
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 199
Lion Biotech Enters into Licensing Agreement with National Institutes of Health 201
Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 202
JSK Therapeutics Enters Into Licensing Agreement with NIH Office of Technology Transfer 203
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 204
Genesis Biopharma Enters Into Patent Licensing Agreement With National Institutes Of Health 205
Lion Biotech Amends Licensing Agreement with National Institutes of Health 206
Biologics Resources Enters into Licensing Agreement with National Institutes of Health 207
uniQure Amends Licensing Agreement with National Institutes of Health for AAV5 Products 208
Microbiotix Receives Notice for Exclusive Patent License from National Institutes of Health 209
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 210
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 211
Butantan Institute Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 212
Vtesse Enters into Licensing Agreement with National Institutes of Health for Cyclodextrins 213
Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 214
Exxell BIO Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 216
Peptron Enters into Licensing agreement with National Institutes of Health 217
KannaLife Sciences Enters Into Licensing Agreement With NIH 218
Organic Vaccines Enters into Licensing Agreement with National Institutes of Health 219
Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 220
Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 221
Bavarian Nordic Enters into Licensing Agreement with National Institutes of Health 222
Radiation Control Technologies Enters Into Licensing Agreement With National Institutes of Health 223
NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 224
KannaLife Sciences Enters Into Licensing Agreement With NIH-OTT 225
BioDigitalValley Enters Into Licensing Agreement With National Library of Medicine 226
BN ImmunoTherapeutics Enters Into Licensing Agreement With National Institutes of Health 227
Amsterdam Molecular Expands Licensing Agreement With National Institutes Of Health 228
Ariadne Genomics Extends Licensing Agreement With NCI For Pathway Studio 229
U.S. Department of Health and Human Services, Key Employees 230
U.S. Department of Health and Human Services, Other Locations 231
U.S. Department of Health and Human Services, Subsidiaries 231
U.S. Department of Health and Human Services, Joint Venture 233

★海外企業調査レポート[U.S. Department of Health and Human Services-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Sihayo Gold Ltd：企業の戦略・SWOT・財務分析
    Sihayo Gold Ltd - Strategy, SWOT and Corporate Finance Report Summary Sihayo Gold Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • United States Postal Service：企業の戦略的SWOT分析
    United States Postal Service - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Tanzania Electric Supply Co Ltd：電力：M&Aディール及び事業提携情報
    Summary Tanzania Electric Supply Co Ltd (TANESCO), formerly Tanganyika Electric Supply Co Ltd, is a government-owned integrated power company. The company’s operations are regulated by the Ministry of Energy and Minerals. It generates, transmits, distributes and supplies electricity. TANESCO generat …
  • The Ensign Group Inc (ENSG)：企業の財務・戦略的SWOT分析
    The Ensign Group Inc (ENSG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Linamar Corporation (LNR)：企業の財務・戦略的SWOT分析
    Linamar Corporation (LNR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Cherkizovo Group OJSC (GCHE)：企業の財務・戦略的SWOT分析
    Cherkizovo Group OJSC (GCHE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Truman Arnold Companies, Inc.
    Truman Arnold Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Truman Arnold Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • SSA Marine Inc：企業の戦略的SWOT分析
    SSA Marine Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Guardian Industries Corp.：企業の戦略・SWOT・財務情報
    Guardian Industries Corp. - Strategy, SWOT and Corporate Finance Report Summary Guardian Industries Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Gedeon Richter Plc：企業の戦略・SWOT・財務情報
    Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report Summary Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Allianz Insurance plc：企業の戦略・SWOT・財務情報
    Allianz Insurance plc - Strategy, SWOT and Corporate Finance Report Summary Allianz Insurance plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Independent News & Media Plc：企業の戦略的SWOT分析
    Independent News & Media Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Lantheus Medical Imaging Inc：医療機器：M&Aディール及び事業提携情報
    Summary Lantheus Medical Imaging Inc (Lantheus Medical), a subsidiary of Lantheus Holdings, Inc., develops, manufactures, and commercializes diagnostic imaging agents and products for the diagnosis of conditions that affect heart, brain, lungs and other organs using echocardiography and nuclear imag …
  • Compagnie Financiere Richemont SA：企業の戦略・SWOT・財務情報
    Compagnie Financiere Richemont SA - Strategy, SWOT and Corporate Finance Report Summary Compagnie Financiere Richemont SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Zuger Kantonalbank AG：企業の戦略・SWOT・財務分析
    Zuger Kantonalbank AG - Strategy, SWOT and Corporate Finance Report Summary Zuger Kantonalbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Whiting Petroleum Corporation：企業の戦略・SWOT・財務情報
    Whiting Petroleum Corporation - Strategy, SWOT and Corporate Finance Report Summary Whiting Petroleum Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Sunrise Medical (US) LLC：企業の戦略的SWOT分析
    Sunrise Medical (US) LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Macfarlane Group Plc (MACF)：企業の財務・戦略的SWOT分析
    Macfarlane Group Plc (MACF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Endava Limited
    Endava Limited - Strategy, SWOT and Corporate Finance Report Summary Endava Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • WPG Resources Ltd (WPG)：企業の財務・戦略的SWOT分析
    Summary WPG Resources Ltd (WPG) is a mining and mineral exploration company. The company’s business activities include acquisition, exploration, and development of gold, nickel, base metals, iron ore, and coal properties in South Australia. Its projects comprise Tunkillia gold project, Tarcoola gold …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆